HSD17B4 and posterior cortical atrophy: hsd17b4 is a potential biomarker for the diagnosis of prostate cancer (PCa), and studies implicate an increase in hsd17b4 expression related to poor prognosis for prostate cancer, upregulating hsd17b4 enhanced the malignant capacities of PCa cells, while hsd17b4 knockdown inhibited these capacities [33].